The Lower the ApoB, the Better: Now, How Does ApoB Fit in the Upcoming Era of Targeted Therapeutics?

Mohamed B Elshazly^{1

2}, Renato Quispe²

Affiliations

¹ Division of Cardiology, Medical University of South Carolina, Charleston (M.B.E.).
² Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease; Baltimore, MD (M.B.E., R.Q.).

Editorial

Mohamed B Elshazly et al. Circulation. 2022.

. 2022 Aug 30;146(9):673-675.

doi: 10.1161/CIRCULATIONAHA.122.061188. Epub 2022 Aug 29.

Mohamed B Elshazly^{1

2}, Renato Quispe²

¹ Division of Cardiology, Medical University of South Carolina, Charleston (M.B.E.).
² Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease; Baltimore, MD (M.B.E., R.Q.).

No abstract available

Keywords: Editorials; PCSK9 inhibitors; acute coronary syndrome; apolipoprotein B-100; cholesterol, LDL; lipoprotein (a).

Comment on

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.